Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04390399 · ClinicalTrials.gov registry record · Phase 2
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by ImmunityBio.
- Active
- Registry status
- Phase 2
- Development phase
- 328
- Enrollment target
- 4
- Study locations
NCT04390399 is a Phase 2 study of Pancreatic Cancer that is active but no longer recruiting, run by ImmunityBio. The registered enrollment target is 328 participants, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (16% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT04390399, a Phase 2 study of Pancreatic Cancer, is active but no longer recruiting, sponsored by ImmunityBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 328 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase 2, three-cohort (2 randomized and 1 single-arm), open-label study to evaluate the comparative efficacy and overall safety of standard-of-care chemotherapy versus standard-of-care chemotherapy in combination with aldoxorubicin HCl, N-803, and PD-L1 t-haNK in subjects with locally advanced or metastatic pancreatic cancer. Each treatment setting (ie, first line maintenance, second line, or third line or greater) will be evaluated independently as a separate cohort.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- BIOLOGICAL PD-L1 t-haNK
- BIOLOGICAL N-803
- DRUG Aldoxorubicin HCl
Study Locations (4)
California
- Chan Soon-Shiong Institute for Medicine - El Segundo
- Hoag memorial Presbyterian Hospital - Newport Beach
New Jersey
- Astera Cancer Care - East Brunswick
South Dakota
- Avera Cancer Institute - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2020-07-21 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04390399
The ClinicalTrials.gov registry entry for NCT04390399 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (16% lower). The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine is the first listed.
NCT04390399 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, New Jersey, South Dakota.
Frequently Asked Questions
What is clinical trial NCT04390399 about?
NCT04390399 is a clinical study titled "Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer". This is a phase 2, three-cohort (2 randomized and 1 single-arm), open-label study to evaluate the comparative efficacy and overall safety of standard-of-care chemotherapy versus standard-of-care chemotherapy in combination with aldoxorubicin HCl, N-803, and PD-L1 t-haNK in subjects with locally adva...
What is the current status of trial NCT04390399?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 328 participants. The study started on 2020-07-21. Estimated completion is 2026-05-31.
What conditions does trial NCT04390399 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT04390399?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), PD-L1 t-haNK (BIOLOGICAL), N-803 (BIOLOGICAL), Aldoxorubicin HCl (DRUG).
Who is sponsoring clinical trial NCT04390399?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04390399 being conducted?
This trial has 4 study locations across California, New Jersey, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.